## SOFIVA GENOMICS



## Stock Code 6615 Investor Conference

2024 / 12 / 18

Chairman Yi-Ning Su, MD. Ph.D

#### Disclaimer

All statements for investors contain information that represent, other than historical facts, SOFIVA's plans and forward-looking statements are based upon management's current assumptions.

Environmental changes and other important factors could cause actual results to

differ materially from those expressed in our statements.

Investors should carefully consider the investment objectives and risks before

investing.

SOFIVA


## **SOFIVA - The Dual Operating Strategy**

Maternal Fetal Medicine

**Precision Cancer Medicine** 

Genetic Screening Category	Servicing Specialty	Target         IVF         Embryo Screening         Pre-pregnant couples         Pregnant couples         Child         Newborn         All Target Audience (Pre-Cancer & Patient)	
Reproductive	IVF Center		
Prenatal	OB-GYN		
Newborn	Pediatrics, Neonatology		
Cancer	Cancer-related Specialty		
Rare Disease	Genetics-related Specialty	All Target Audience	
SOF Precision Medicine	Treatment-related Specialty	All Target Audience	

#### **Protecting Life and Health with 6 Core Testing Services**




#### Maternal Fatal Medicine and Precision Cancer Medicine One Stop Service


Reproductive	Prenatal	Newborn	
• PGT-M	• NIPS	• Baby Scan	
• PGT-A • niPGT-A	• Array • Karyotyping • Carrier Scan	<ul> <li>Hearing Loss Genetic Screening</li> <li>CCHS Genetic Screening</li> <li>Congenital CMV Infection Screening</li> </ul>	
Rare Diseases <ul> <li>Hearing Loss Genetic Test v1.0/v2.0/v3.0</li> </ul>	SMA Genetic Testing-SMN gene     Fragile X Genetic Testing-FMR1 gene	<ul> <li>Atopic Dermatitis Genetic Screening</li> <li>-FLG gene</li> </ul>	
Achondroplasia	• Thalassemia Genetic Testing-HBA,HBB gene	Precision Medicine	
<ul><li>Osteogenesis Imperfecta</li><li>Duchenne Muscular Dystrophy</li></ul>	Folate Metabolism Genetic Testing-MTHFR gene Cancer	HRD Status     CGP Genetic Test	
<ul> <li>Wilson's Disease</li> <li>Marfan Syndrome</li> <li>Whole Exon Sequencing Genetic Testing</li> <li>SOFIVA GENOMICS</li> </ul>	<ul> <li>Cancer Monitor</li> <li>Cancer Scan v1.0/v2.0</li> <li>Cancer Risk v1.0/v2.0</li> <li>HPV Screening</li> </ul>	<ul> <li>COP Genetic Test</li> <li>BRCA1/2 Genetic Testing</li> <li>Endometrial Cancer Genetic Subtypes</li> <li>Prostate Cancer Genetic Testing</li> </ul>	

# **Operating Strategy**

SOFIVA



Source: National Development Council



#### Focus on Advancing High-Level Projects on Revenue 113Q3 compared to 112Q3 **Prenatal** Newborn **Prenatal** Array v2.0/v3.0 Carrier Scan v2.0/v3.0 Baby Scan v2.0/v3.0 Growth Growth Growth 8% 11% 35% ... 1.... The goal is to boost revenue per capita from testing. We will refine market direction and promotion. 113 113 113 113 113 112 112 112 113 113 112 112 112 113 113 112 112 112 Q3 **Q**2 Q3 Q1 **Q**2 Q3 **Q**2 Q3 **Q**4 Q1 Q3 **Q**2 Q3 Q4 Q1 **Q**2 Q4

## **Cancer Products Aligned with Clinical Requirements**

#### 1. Clinical Institutions

#### **Partner Institutions: Over 190 Hospitals and Clinics**

Clinical Institutions Medical Centers: Over 10 **Regional Hospitals: Over 100** 

SOFIVA GENOMICS

AB

+

AB

	品項	基因數	檢體	特色	適用科別
1		6	組織+血液		婦科
2		13	組織 or 血液		消化
3		13	組織 or 血液	泌尿道上皮癌: FDA用藥+臨床試驗用藥	泌尿
4		26	組織 or 血液		胸腔
5		26	組織 or 血液	乳癌: FDA用藥+臨床試驗用藥	乳外
6	癌監控基因檢測-大腸癌	26	組織 or 血液	大腸癌: FDA用藥+臨床試驗用藥	直外
7	HRD檢測	28	<i>组織</i> +血液	在台灣已收室1000多室例	<u> / 乳 小 / 沁 尿</u>
	Multiple		Multiple	Unique	Wide Range of
	Products		Sample	可用液 全球第一 Testing <sup>目第</sup>	Applicable
13	癌風險-大腸癌基因檢測		Typec	Features	Specialties
14	癌風險-婦癌基因檢測		Types	reatures	Specialities
15	癌風險基因檢測 v1.0	67	組織 or 皿液	合癌別	
16	癌風險基因檢測 v2.0	151	組織 or 血液	各癌別	S@FIVA
17	癌監控基因檢測 v2.2	197	組織+血液	全方位: FDA用藥+復發相關基因	GENOMICS 1
18	癌監控基因檢測 v3.0	249	組織+血液	全方位: FDA用藥+臨床試驗用藥+復發相關基因 🏸 🗸	全科別

### **Cancer Products Compliant with Government Policies**

2. NGS Genetic Laboratory - Accredited Laboratory Operations




Pathological Slides Biological Analysis



11

#### Cancer Products Compliant with NGS Health Insurance Coverage

3. NGS Genetic Testing <u>Laboratory and Testing Compliant with</u> <u>NGS Health Insurance Coverage</u>



## **Current Status of Cancer Product Review**

Testing Items Awaiting

Simplified Review

十睡症

#### 次世代基因定序檢測實驗室審查慢 醫事司:改電子化

1-21 03:49 聯合叔 / 记老注能开 / 台北報源



「次世代基因定序檢測」(NGS) 不如預期,一位不具名腫瘤科醫師表示,部分關鍵在 (IDTS) 核 准速度太慢,建議明文規定適當審查期限,讓醫療院所掌握完成時間。

義大癌治療醫院副院長饒坤銘表示,NGS採「事前報備、事後審查」制度,一日癌友

#### The Laboratory Review Process is **Experiencing Delays**

除非是檢體瑕疵, 每法完成檢測才給予退費 , 醫院應先與病人說明溝涌。建議健 保署盤點NGS審查、收費、退費等流程,使其更為流暢,並讓更多醫院加入檢測,オ

能提高服務量能,「不要讓病人想做,卻沒很

衛福部醫事司副司長劉玉菁指出,實驗室開 納入特管辦法前的送審個案均已審查完畢 八一件,仍有四二八四件待審。為加速

件採電子化,節省人工審查及書面往來時間,期望送檢案件儘速完成審查。

BRCA 1/2基因檢測為最多,共432件。

2024-11-16 10:50 聯合報/ 記者林琼風/台北即時報導

應用及健保給付現況

NGS給付累計842件、肺癌最多台大癌醫院長曝有1限制

の NTU CANCER CENTER 合大癌醫中心



**癌16**件 ,田狀腺癌12 163件,小於100基因的「小套組」247件,

+ 肺病


## Cancer Product Response Strategies

Slow Review Process


Establish a Dedicated Team to Handle the Process



Monitor the Review Process Speed



## **Review Process and Progress**




# Strategic Expansion into the Health Check-up Market

## Cancer: The Leading Cause of Death


### Top 10 Cancer Causes of Death

In 2021, 120,000 New Cancer Cases (Published in 2023) In 2023, 50,000 Cancer Deaths (Published in 2024)




#### Strengthen the National Cancer Prevention and Control Program






Source : Executive Yuan Gender Equality Committee; National Health Insurance Administration, 2022 Adult Preventive Health Services Payment Data File; Ministry of the Interior Population Statistics (Year-End Population)

19




## The world 's top medical journals NEJM




# Strategic Expansion into the Health Check-up Market Cancer Scan Liquid Biopsy

SOFIVA





#### The Advantages of Using ctDNA) for Cancer Screening



The Innovation 3(4): 100259, July 12, 2022


#### Liquid Biopsy

- Can detect <u>early-stage cancer</u>
- Can provide information on <u>multiple types of</u> cancer simultaneously
- A simple blood draw is sufficient
- Provide genetic information about the tumor

#### Traditional Cancer Screening

- Less sensitive
- Targets only one type of cancer at a time
- Some cancers do not have suitable detection methods
- Mostly invasive testing
- Cannot provide genetic information about the tumor








## **Operating Performance**

#### **Operational Performance**

#### Statements of Comprehensive Income of last 3 years







#### **Revenue Trend : The Last 6 Months**

**Revenues of Last 6 Months** 



### **Investment Performance**

(In Thousands of New Taiwan Dollars)

DIANTHUS CO.,Ltd						
Statements of Comprehensive Income						
	2021	2022	2023			
Sales Revenue	599,944	689,795	695,831			
Comprehensive Income	171,767	253,022	142,929			
Capital Stock	895,000	895,000	895,000			
		Z				
Investment from Sofiva	148,250	148,250	148,250			
Shareholding Ratio of Sofiva	16.56%	16.56%	16.56%			
Investment Income of Sofiva	31,047	41,902	23,671			



SOFIVA GENOMICS Co., Ltd. www.sofivagenomics.com T +886-2-2382-6615 F +886-2-2382-6617

Add No.27, Baoqing Rd., Zhongzheng Dist., Taipei City 100